Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis
Authors Zhang M, Tan X, Huang J, Xie L, Wang H, Shi J, Lu W, Lv Z, Mei H, Liang C
Received 19 August 2015
Accepted for publication 21 January 2016
Published 19 April 2016 Volume 2016:9 Pages 2181—2192
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ram Prasad
Peer reviewer comments 4
Editor who approved publication: Dr Jianmin Xu
Meng Zhang,1,2,* Xiuxiu Tan,1,* Junjie Huang,3,* Lijuan Xie,1 Hao Wang,1 Jizhou Shi,4 Wei Lu,1 Zhaojie Lv,1 Hongbing Mei,1 Chaozhao Liang2
1Department of Urology, Shenzhen Second People’s Hospital, Clinical Medicine of Anhui Medical University, 2Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, 3Department of Hematology, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 4Department of Urology, Shengli Oilfield Central Hospital, Dongying, Peoples Republic of China
*These authors contributed equally to this work
Background: Several epidemiological studies have illustrated that polymorphisms in interleukin-2 (IL-2) were associated with diverse cancer types. However, recently published statistics were inconsistent and inconclusive. Therefore, the current meta-analysis was performed to elaborate the effects of IL-2 polymorphisms (rs2069762 and rs2069763) on cancer susceptibility.
Material and methods: A total of 5,601 cancer cases and 7,809 controls from 21 published case–control studies were enrolled in our meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between IL-2 polymorphisms and cancer susceptibility.
Results: Our study demonstrated an increased susceptibility to cancer in rs2069762 (G vs T: OR =1.268, 95% CI =1.113–1.445; GG vs TT: OR =1.801, 95% CI =1.289–2.516; GT vs TT: OR =1.250, 95% CI =1.061–1.473; GG + GT vs TT: OR =1.329, 95% CI =1.118–1.579; GG vs GT + TT: OR =1.536, 95% CI =1.162–2.030). In the subgroup analysis, increased susceptibility to cancer was identified in the hospital-based group and PHWE<0.05 (P-value of the Hardy–Weinberg equilibrium [HWE]) group. In addition, a positive association with cancer susceptibility was observed among both Chinese and non-Chinese. However, no relationship was detected between the rs2069763 polymorphism of IL-2 and cancer susceptibility.
Conclusion: To conclude, rs2069762 polymorphism of IL-2 contributed to an increased susceptibility to cancer, whereas no association was identified between rs2069763 polymorphism and cancer susceptibility. Further detailed studies are warranted to confirm our findings.
Keywords: IL-2, polymorphism, cancer, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]